What is ABclonal Technology?
ABclonal Technology operates as a specialized supplier of research-use biological reagents, providing essential tools such as antibodies, proteins, and peptides to the global scientific community. By focusing on experimental consistency and high-quality molecular biology products, the company has carved out a significant niche in the chemicals and related products manufacturing industry. Its business model is deeply integrated into laboratory research workflows, offering customized solutions that address the complex needs of academic and commercial research institutions. Through its commitment to precision and reliability, ABclonal Technology has established itself as a vital partner for researchers seeking to improve the reproducibility and quality of their experimental outcomes.
How much funding has ABclonal Technology raised?
ABclonal Technology has raised a total of $92.9M across 1 funding round:
Series C
$92.9M
Series C (2021): $92.9M with participation from Kinghall Ventures, Sigma Square Capital, LYFE Capital, Sequoia Capital China, and Lucion Capital
Key Investors in ABclonal Technology
Sigma Square Capital
Sigma Square Capital is a research-driven investment firm established in 2015 that focuses on high-growth sectors including healthcare, consumer upgrades, and the internet.
Sequoia Capital China
Sequoia Capital is a globally recognized venture firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across various stages of growth.
Kinghall Ventures
Kinghall Ventures is an institutional investor participating in the funding round to support the long-term growth and strategic development of the company.
What's next for ABclonal Technology?
With the successful closure of this major strategic investment, ABclonal Technology is poised to leverage its enhanced financial position to drive innovation in its core product lines. The company is expected to prioritize the expansion of its manufacturing capabilities and the diversification of its assay-related materials to meet the evolving demands of the life sciences market. Furthermore, the involvement of seasoned venture capital partners suggests a strategic focus on scaling market share and potentially exploring new geographic territories. As the company continues to refine its operational efficiency, it remains a key player to watch for advancements in biological research infrastructure and laboratory support services.
See full ABclonal Technology company page
